share_log

Insider Purchase: Director at $PBI (PBI) Buys 300 Shares

Insider Purchase: Director at $PBI (PBI) Buys 300 Shares

內部購買:$PBI (PBI) 的董事購買了300股
Quiver Quantitative ·  11/23 04:15

PAUL J. EVANS, a director at $PBI ($PBI), bought 300 shares of the company on 11-20-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings by approximately 1.0%. Following this trade, they now own 29,000 shares of $PBI stock.

$PBI Insider Trading Activity

$PBI insiders have traded $PBI stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.

Here's a breakdown of recent trading of $PBI stock by insiders over the last 6 months:

  • PAUL J. EVANS has traded it 5 times. They made 5 purchases, buying 29,000 shares and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$PBI Hedge Fund Activity

We have seen 145 institutional investors add shares of $PBI stock to their portfolio, and 119 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

  • VANGUARD GROUP INC added 1,443,692 shares (+7.8%) to their portfolio in Q3 2024
  • CAPITAL MANAGEMENT CORP /VA removed 1,437,494 shares (-34.6%) from their portfolio in Q3 2024
  • ASSENAGON ASSET MANAGEMENT S.A. added 1,187,531 shares (+2894.2%) to their portfolio in Q3 2024
  • CLIFFORD CAPITAL PARTNERS LLC removed 930,972 shares (-25.4%) from their portfolio in Q3 2024
  • CANADA PENSION PLAN INVESTMENT BOARD added 656,900 shares (+31281.0%) to their portfolio in Q3 2024
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 655,275 shares (-18.6%) from their portfolio in Q3 2024
  • BLACKROCK, INC. added 653,565 shares (+3.9%) to their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.


This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論